Alexion Jumps On Biotech Merger Bandwagon With $855 Million Buy

Alexion Pharmaceuticals (ALXN) will snap up Wilson Therapeutics for $855 million in a move to diversify from its blockbuster drug Soliris and its follow-up, ALXN1210, an analyst said Wednesday.

X

The acquisition of Wilson adds a "much-needed" late-stage asset, RBC analyst Kennen MacKay said in a note to clients. Alexion's biggest product, Soliris, brought in 88% of sales in 2017. Soliris treats two blood diseases and a neuromuscular condition.

"Investors have increasingly focused on...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Alexion Pharmaceuticals [+]    ALXN [+]    Wilson Therapeutics [+]    Soliris [+]    Wilson [+]    RBC [+]    Kennen MacKay [+]    Investors [+]   

More #news: